Comprehensive Income (Loss), Net of Tax, Attributable to Parent of Vistagen Therapeutics, Inc. from 30 Sep 2012 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Vistagen Therapeutics, Inc. quarterly and annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD history and change rate from 30 Sep 2012 to 31 Dec 2025.
  • Vistagen Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 31 Dec 2025 was $18,900,000, a 34% decline year-over-year.
  • Vistagen Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending 31 Dec 2025 was $67,044,000, a 42% decline year-over-year.
  • Vistagen Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was $51,413,000, a 75% decline from 2023.
  • Vistagen Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was $29,362,000, a 50% increase from 2022.
  • Vistagen Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was $59,248,000.
Source SEC data
View on sec.gov
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)

Vistagen Therapeutics, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $67,044,000 $18,900,000 -$4,800,000 -34% 01 Oct 2025 31 Dec 2025 10-Q 12 Feb 2026 2026 Q3
Q3 2025 $62,244,000 $19,404,000 -$6,463,000 -50% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2026 Q2
Q2 2025 $55,781,000 $15,099,000 -$4,368,000 -41% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2026 Q1
Q1 2025 $51,413,000 $13,641,000 -$4,120,000 -43% 01 Jan 2025 31 Mar 2025 10-K 17 Jun 2025 2025 FY
Q4 2024 $47,293,000 $14,100,000 -$7,750,000 -122% 01 Oct 2024 31 Dec 2024 10-Q 12 Feb 2026 2026 Q3
Q3 2024 $39,543,000 $12,941,000 -$6,353,000 -96% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2026 Q2
Q2 2024 $33,190,000 $10,731,000 -$3,828,000 -55% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2026 Q1
Q1 2024 $29,362,000 $9,521,000 01 Jan 2024 31 Mar 2024 10-K 17 Jun 2025 2025 FY
Q4 2023 $6,350,000 01 Oct 2023 31 Dec 2023 10-Q 13 Feb 2025 2025 Q3
Q3 2023 $6,588,000 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2025 Q2
Q2 2023 $6,903,000 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2025 Q1
Q4 2016 $2,638,500 -$491,900 -23% 01 Oct 2016 31 Dec 2016 10-Q 13 Feb 2017 2016 Q3
Q3 2016 $3,101,100 +$3,947,000 +56% 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2016 2016 Q2
Q2 2016 $1,967,100 +$27,557,000 +93% 01 Apr 2016 30 Jun 2016 10-Q 12 Aug 2016 2016 Q1
Q4 2015 $2,146,600 -$1,056,300 -97% 01 Oct 2015 31 Dec 2015 10-Q 13 Feb 2017 2016 Q3
Q3 2015 $7,048,100 -$5,027,200 -249% 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016 2016 Q2
Q2 2015 $29,524,100 -$24,970,800 -548% 01 Apr 2015 30 Jun 2015 10-Q 12 Aug 2016 2016 Q1
Q4 2014 $9,489,100 $1,090,300 -$1,221,300 -932% 01 Oct 2014 31 Dec 2014 10-Q 17 Feb 2015 2015 Q3
Q3 2014 $8,267,800 $2,020,900 -$561,100 -38% 01 Jul 2014 30 Sep 2014 10-Q 19 Nov 2014 2014 Q2
Q2 2014 $7,706,700 $4,553,300 -$4,739,000 -2552% 01 Apr 2014 30 Jun 2014 10-Q 12 Aug 2014 2014 Q1
Q1 2014 $2,967,700 $1,824,600 01 Jan 2014 31 Mar 2014 10-K 25 Jun 2014 2014 FY
Q4 2013 $131,000 +$5,466,000 01 Oct 2013 31 Dec 2013 10-Q 17 Feb 2015 2015 Q3
Q3 2013 $1,459,800 +$495,900 +25% 01 Jul 2013 30 Sep 2013 10-Q 19 Nov 2014 2014 Q2
Q2 2013 $185,700 01 Apr 2013 30 Jun 2013 10-Q 12 Aug 2014 2014 Q1
Q4 2012 $5,335,000 01 Oct 2012 31 Dec 2012 10-Q 14 Feb 2014 2013 Q3
Q3 2012 $1,955,700 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013 2013 Q2

Vistagen Therapeutics, Inc. Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $51,413,000 -$22,051,000 -75% 01 Apr 2024 31 Mar 2025 10-K 17 Jun 2025 2025 FY
2023 $29,362,000 +$29,886,000 +50% 01 Apr 2023 31 Mar 2024 10-K 17 Jun 2025 2025 FY
2022 $59,248,000 01 Apr 2022 31 Mar 2023 10-K 11 Jun 2024 2024 FY
2013 $2,967,700 +$9,919,000 +77% 01 Apr 2013 31 Mar 2014 10-K 25 Jun 2014 2014 FY
2012 $12,886,700 01 Apr 2012 31 Mar 2013 10-K 25 Jun 2014 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.